IP Library Granted Patent US 10,087,195
Granted Patent B2
US 10,087,195 · App. 15/314,006 · Granted Oct 2, 2018

Certain protein kinase inhibitors

Inventors: Weibo Wang (Moraga, CA); Xingdong Zhao (Moraga, CA); Tongshuang Li (Surrey, CA); Qiang Tian (Chongqing, CN); Huajie Zhang (Chongqing, CN); Haohan Tan (Chongqing, CN); Xianlong Wang (Chongqing, CN); Qihong Liu (Chongqing, CN); Zhifu Li (Chongqing, CN); Weipeng Zhang (Chongqing, CN); Zhifang Chen (Chongqing, CN); Lihua Jiang (Chongqing, CN); Yanxin Liu (Chongqing, CN); Li Linghu (Chongqing, CN); Min Lin (Chongqing, CN); Jing Sun (Chongqing, CN)
Assignees: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD.; CHONGQING FOCHON PHARMACEUTICAL CO., LTD.
C07D519/00A61K31/519A61K31/53A61K31/5377C07D401/12C07D401/14C07D403/12C07D403/14C07D487/04C07D491/048C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,087,195
App. No.
15/314,006
Granted
Oct 2, 2018
Kind
B2
Abstract

Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Claims (119)

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

X is C;

Y is S;

6-5 membered fused ring system A-B is

Q is selected from aryl and heteroaryl;

R 1 is selected from: hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent independently selected from R 6a , and wherein aryl and heteroaryl are each unsubstituted or substituted with at least one substituent independently selected from R 6b ;

R 2 is selected from: hydrogen, halogen, hydroxyl, CN, C 1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C 3 -10 cycloalkyl, C3-10 cycloalkyl-C 14 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R 6a , and each aryl and heteroaryl is unsubstituted or substituted with at least one substituent independently selected from R 6b ;

R 3 and R 4 are independently selected from: hydrogen, C 1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, and C3-10 cycloalkyl; wherein alkyl, alkenyl, alkynyl, and cycloalkyl are each unsubstituted or substituted with at least one substituent independently selected from R 6a ; or R 3 and R 4 together with the nitrogen atoms to which they are attached form a 4-12 membered ring containing 0, 1, 2 or 3 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with for 1 or 2 R 6a groups;

with the proviso that when R 3 and R 4 are both hydrogen, R 2 is not aryl or heteroaryl;

each R 5 is independently selected from: hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, —OR 8 , —NR 7 S(O) r R 8 , —NO 2 , -halogen, —S(O) r R 7 , —SR 8 , —S(O) 2 0R 7 , —OS(O) 2 R 8 , —S(O),NR 7 R 8 , —NR 7 R 8 , —O(CR 9 R 10 ) t NR 7 R 8 , —C(O)R 7 , —CO 2 R 8 , —CO 2 (CR 9 R 10 ) t CONR 7 R 8 , —OC(O)R 7 , —CN, —C(O)NR 7 R 8 , —NR 7 C(O)R 8 , —OC(O)NR 7 R 8 , —NR 7 C(O)OR 8 , —NR 7 C(O)NR 7 R 8 , —CR 7 (N-OR 8 ), —CHF 2 , —CF 3 , —OCHF 2 , and —OCF 3 ; wherein C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, and C 3-10 cycloalkyl are each unsubstituted or substituted with at least one substituent independently selected from R 6a ;

each R 6a is independently selected from: -C 1-10 alkyl, —C 2-10 alkenyl, -C 2-10 alkynyl, -C 3-10 cycloalkyl, —OR 8 , —NR 7 S(O) r R 8 , —NO 2 , -halogen, —S(O) r R 7 , —SR 8 , —S(O) 2 OR 7 , —OS(O) 2 R 8 , —S(O) r NR 7 R 8 , —NR 7 R 8 , —(CR 9 R 10 ) t OR 8 , —(CR 9 R 10 ) t NR 7 R 8 , —(CR 9 R 10 ) t SR 8 , —(CR 9 R 10 ) t S(O) r ,R 8 , —(CR 9 R 10 ) t CO 2 R 8 , —(CR 9 R 10 ) t CONR 7 R 8 , —(CR 9 R 10 ) t NR 7 CO 2 R 8 , —(CR 9 R 10 ) t OCONR 7 R 8 , —(CR 9 R 10 ) t NR 7 CONR 7 R 8 , —(CR 9 R 10 ) t NR 7 SO 2 NR 7 R 8 , —O(CR 9 R 10 ) t NR 7 R 8 , —C(O)R 7 , —C(O)(CR 9 R 10 ) t OR 8 , —C(O)(CR 9 R 10 ) t NR 7 R 8 , —C(O)(CR 9 R 10 ) t SR 8 , —C(O)(CR 9 R 10 ) t S(O) r R 8 , —CO 2 R 8 , —CO 2 (CR 9 R 10 ) t CONR 7 R 8 , —OC(O)R 7 , —CN, —C(O)NR 7 R 8 , —NR 7 C(O)R 8 , —OC(O)NR 7 R 8 , —NR 7 C(O)OR 8 , —NR 7 C(O)NR 7 R 8 , —CR 7 (N—OR 8 ), —CHF 2 , —CF 3 , —OCHF 2 , and —OCF 3 ;

each R 6b is independently selected from: R 6a , aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl;

each R 7 and each R 8 are independently selected from: hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, cycloalkyl, cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl; wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, independently selected from R 6a , and aryl and heteroaryl are each unsubstituted or substituted with at least one substituent independently selected from R 6b ; or R 7 and R 8 together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1, or 2 additional heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 or 2 R 6b groups;

each R 9 and each R 10 are independently selected from: hydrogen, C 1-10 , C 2-10 alkenyl, C 2-10 alkynyl, cycloalkyl, cycloalkyl-C1-4 alkyl, heterocyclyl, heterocyclyl-C1-4 alkyl, aryl, aryl-C1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl; or R 9 and R 10 together with the carbon atom(s) to which they are attached form a ring of 3 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 or 2 R 6a groups;

m is independently selected from 0, 1, 2, and 3;

each r is independently selected from 1 and 2;

each t is independently selected from 1, 2, and 3.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Q is selected from heteroaryl.

3. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein Q is selected from pyridyl, pyridazinyl and 5,6,7,8-tetrahydro-1,6-naphthyridinyl.

4. The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein Q is selected from pyridin-2-yl, pyridazin-3-yl and 5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from hydrogen, C 1-10 alkyl, heterocyclyl and heterocyclyl-C 1-4 alkyl, wherein heterocyclyl is unsubstituted or substituted with at least one substituent independently selected from R 6a , wherein each R 6a is independently selected from C 1-10 alkyl, —NR 7 R 8 , —(CR 9 R 10 ) t OR 8 , —OR 8 , —C(O)R 7 , —(CR 9 R 10 ) t S(O) r R 8 ; wherein R 7 , R 8 , R 9 , R 10 , t and r are described as in claim 1 .

6. The compound of claim 5 or a pharmaceutically acceptable salt thereof, wherein Q is selected from pyridin-2-yl, pyridazin-3-yl, and R 1 is selected from heterocyclyl and heterocyclyl-C 1-4 alkyl groups consisting of the following groups:

each heterocyclyl is unsubstituted or substituted with at least one independently selected from R 6a , wherein each R 6a is independently selected from C 1-10 alkyl, —NR 7 R 8 , —(CR 9 R 10 ) t OR 8 , —OR 8 , —C(O)R 7 , —C(O)NR 7 R 8 , —(CR 9 R 10 ) t S(O) r R 8 ; wherein R 7 , R 8 , R 9 , R 10 , t and r are described as in claim 1 .

7. A compound of claim 5 or a pharmaceutically acceptable salt thereof, wherein R 6a is independently selected from hydrogen, methyl, ethyl, hydroxyl, hydroxymethyl, hydroxyethyl, hydroxyacetyl, methoxymethyl, methoxyethyl, acetyl, hydroxyacetyl, (methyl sulfonyl)ethyl, amino, carbamoyl, methylamino, and dimethylamino.

8. The compound claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from C 3-10 cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with at least one substituent independently selected from R 6a , R 6a is described as in claim 1 .

9. The compound of claim 8 or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from cyclopentyl and cyclohexyl, wherein cyclohexyl is unsubstituted or substituted with methyl.

10. The compound claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are independently selected from hydrogen, C 1-10 alkyl and cyclopropyl.

11. The compound claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 together with the nitrogen atoms to which they are attached form azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, and morpholino, wherein the formed ring is unsubstituted or substituted with methyl, hydroxyl, and methoxy.

12. The compound claim 1 or a pharmaceutically acceptable salt thereof, wherein R 5 is independently selected from hydrogen, C 1-10 alkyl and —C(O)R 7 , wherein R 7 is selected from methyl and hydroxymethyl.

13. The compound of claim 1 , selected from

7-cyclopentyl-N,N-dimethyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)thieno[3,2-d]pyrimidine-6-carboxamide,

(S)-7-cyclopentyl-N,N-dimethyl-2((5-(3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazin-7(1H)-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

(R)-7-cyclopentyl-N,N-dimethyl-2-((5-(3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazin-7(1H)-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

(R)-7-cyclopentyl-N,N-dimethyl-2-((5-(morpholin-2-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

2-((5-(4-aminopiperidin-1-yl)pyridin-2-yl)amino)-7-cyclopentyl-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((5-(4-(methylamino)piperidin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(S)-7-cyclopentyl-2-((5-(3-(methoxymethyl)piperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(S)-7-cyclopentyl-2-((5-(3-(methoxymethyl)-4-methylpiperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(S)-7-cyclopentyl-2-((5-(4-ethyl-3-(methoxymethyl)piperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(S)-7-cyclopentyl-2-((5-(3-(hydroxymethyl)piperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(S)-7-cyclopentyl-2-((5-(3-(hydroxymethyl)-4-methylpiperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(S)-7-cyclopentyl-2-((5-(4-ethyl-3-(hydroxymethyl)piperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(R)-7-cyclopentyl-2-((5-(3-(methoxymethyl)piperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(R)-7-cyclopentyl-2-((5-(3-(methoxymethyl)-4-methylpiperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(R)-7-cyclopentyl-2-((5-(4-ethyl-3-(methoxymethyl)piperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(R)-7-cyclopentyl-2-((5-(3-(hydroxymethyl)piperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(R)-7-cyclopentyl-2-((5-(3-(hydroxymethyl)-4-methylpiperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(R)-7-cyclopentyl-2-((5-(4-ethyl-3-(hydroxymethyl)piperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((5-(piperidin-4-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((5-(1-methylpiperidin-4-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

2-((5-(6-amino-3-azabicyclo[3.1.0]hexan-3-yl)pyridin-2-yl)amino)-7-cyclopentyl-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-ylmethyl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((5-((4-methylpiperazin-1-yl)methyl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

2-((5-((1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-2-yl)amino)-7-cyclopentyl-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((5-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

(R)-7-cyclopentyl-2-((5-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

(S)-7-cyclopentyl-2-((5-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

2-((5-((1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridin-2-yl)amino)-7-cyclopentyl-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

2-((5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-2-yl)amino)-7-cyclopentyl-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((5-(6-methyl-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((5-(6-ethyl-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((5-((7R,8aR)-7-hydroxyhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((5-((7S,8aR)-7-hydroxyhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((5-((7R,8aS)-7-hydroxyhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

2-((5-(3,6-diazabicyclo[3.2.0]heptan-3-yl)pyridin-2-yl)amino)-7-cyclopentyl-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((5-(6-methyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((5-(6-ethyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((6-(piperazin-1-yl)pyridazin-3-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((6-(4-methylpiperazin-1-yl)pyridazin-3-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

2-((6-(4-acetylpiperazin-1-yl)pyridazin-3-yl)amino)-7-cyclopentyl-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((6-(4-(2-hydroxyacetyl)piperazin-1-yl)pyridazin-3-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((6-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)pyridazin-3-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((5-(4-(2-hydroxyethyl)piperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((5-(4-(2-methoxyethyl)piperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N,N-dimethyl-2-((5-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((5-(4-ethylpiperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-2-((5-((3S,5R)-3,5-dimethylpiperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide

7-cyclopentyl-N,N-dimethyl-2-((5-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide

7-cyclopentyl-2-((5-((3S,5R)-4-ethyl-3,5-dimethylpiperazin-1-yl)pyridin-2-yl)amino)-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide

7-cyclopentyl-N,N-dimethyl-2-((5-(1-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide

2-((5-(4-carbamoyl-4-(methylamino)piperidin-1-yl)pyridin-2-yl)amino)-7-cyclopentyl-N,N-dimethylthieno[3,2-d]pyrimidine-6-carboxamide

azetidin-1-yl(7-cyclopentyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)methanone,

(7-cyclopentyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(3-methoxyazetidin-1-yl)methanone,

(7-cyclopentyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(3-hydroxyazetidin-1-yl)methanone,

(7-cyclopentyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(piperidin-1-yl)methanone,

(7-cyclopentyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(4-methylpiperazin-1-yl)methanone,

(7-cyclopentyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(piperazin-1-yl)methanone,

7-cyclopentyl-N-cyclopropyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

(7-cyclopentyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(pyrrolidin-1-yl)methanone,

7-cyclopentyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

7-cyclopentyl-N-ethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

(7-cyclopentyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(morpholino)methanone,

azetidin-1-yl(7-cyclopentyl-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)methanone,

(7-cyclopentyl-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(3-methoxyazetidin-1-yl)methanone,

(7-cyclopentyl-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(piperidin-1-yl)methanone,

(7-cyclopentyl-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(4-methylpiperazin-1-yl)methanone,

7-cyclopentyl-N-cyclopropyl-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

(7-cyclopentyl-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(pyrrolidin-1-yl)methanone,

7-cyclopentyl-N-methyl-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

(7-cyclopentyl-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidin-6-yl)(morpholino)methanone,

N,N-dimethyl-7-((1r,4r)-4-methylcyclohexyl)-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

N,N-dimethyl-7-((1r,4r)-4-methylcyclohexyl)-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

N,N-dimethyl-7-((1r,4r)-4-methylcyclohexyl)-2-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

N,N-dimethyl-2-((6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-7-((1r,4r)-4-methylcyclohexyl)thieno[3,2-d]pyrimidine-6-carboxamide,

2-((6-acetyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-N,N-dimethyl-7-((1r,4r)-4-methylcyclohexyl)thieno[3,2-d]pyrimidine-6-carboxamide,

2-((6-(2-hydroxyacetyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)amino)-N,N-dimethyl-7-((1r,4r)-4-methylcyclohexyl)thieno[3,2-d]pyrimidine-6-carboxamide,

N,N-dimethyl-7-((1r,4r)-4-methylcyclohexyl)-2-((6-(piperazin-1-yl)pyridazin-3-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

N,N-dimethyl-7-((1r,4r)-4-methylcyclohexyl)-2-((6-(4-methylpiperazin-1-yl)pyridazin-3-yl)amino)thieno[3,2-d]pyrimidine-6-carboxamide,

2-((6-(4-acetylpiperazin-1-yl)pyridazin-3-yl)amino)-N,N-dimethyl-7-((1r,4r)-4-methylcyclohexyl)thieno[3,2-d]pyrimidine-6-carboxamide,

2-((6-(4-(2-hydroxyacetyl)piperazin-1-yl)pyridazin-3-yl)amino)-N,N-dimethyl-7-((1r,4r)-4-methylcyclohexyl)thieno[3,2-d]pyrimidine-6-carboxamide,

or pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 063241 FRAME: 0423. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 1, 2023
From: CHONGQING FOCHON PHARMACEUTICAL CO., LTD.
To: FOCHON PHARMACEUTICALS, LTD.
Reel/Frame 063939/0646 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2023
From: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD.
To: CHONGQING FOCHON PHARMACEUTICAL CO., LTD.
Reel/Frame 063241/0379 →
CHANGE OF NAME Recorded Apr 3, 2023
From: CHONGQING FOCHON PHARMACEUTICAL CO., LTD.
To: FOCHON PHARMACEUTICALS, LTD.
Reel/Frame 063241/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2017
From: WANG, WEIBO; ZHAO, XINGDONG; LI, TONGSHUANG; TIAN, QIANG; ZHANG, HUAJIE; TAN, HAOHAN; WANG, XIANLONG; LIU, QIHONG; LI, ZHIFU; ZHANG, WEIPENG; CHEN, ZHIFANG; JIANG, LIHUA; LIU, YANXIN; LINGHU, LI; LIN, MIN; SUN, JING
To: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD.; CHONGQING FOCHON PHARMACEUTICAL CO., LTD.
Reel/Frame 041078/0259 →
Continuity (2)
Provisional Application 62003626 · May 28, 2014
Related Publication 20170267696A1 · Sep 21, 2017